Von Eschenbach’s Recusal Does Not Eliminate Conflicts, Democrats Say
This article was originally published in The Pink Sheet Daily
Executive Summary
In letter to Secretary Leavitt, three ranking house members denounce the acting commissioner’s promise of non-involvement in FDA decisions regarding the National Cancer Institute.
You may also be interested in...
GAO Expected To Release Draft Plan B Investigation; Pro-Choice Caucus Urges OTC Approval
Sixty-two members of Congress write to Acting Commissioner von Eschenbach on the Plan B issue.
No Double Duty For Von Eschenbach; Niederhuber To Run NCI
John Niederhuber, recently tapped to be NCI deputy director for translational and clinical sciences, will assume the position of chief operating officer, handling day-to-day management of the cancer institute.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications